Dental management of patients with Alzheimer's disease

General Dentistry

Volumn 53, Issue 4, 2005, Pages 289-296

  Little, James W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; DENTAL CARE; HUMAN; REVIEW;

AGED; ALZHEIMER DISEASE; DENTAL CARE FOR CHRONICALLY ILL; HUMANS;

EID: 25144508662     PISSN: 03636771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Daniel ES. Alzheimer's disease. In: Rakel RE, ed. Conn's current therapy, ed. 56. St. Louis: W.B. Saunders Co.;2004:914-923.
2. Little JW. Behavioral and psychiatric disorders. In: Little JW, Falace DA, Miller CS, Rhodus NL, eds. Dental management of the medically compromised patient, ed. 6. St. Louis: Mosby;2002:439-478.
3. Clinical tours. Available at: www.medconsult.com/Alzheimer'sdisease/ clinicaltours. Accessed May 23, 2004.
4. Patient handouts. Available at: www.medconsult.com/Alzheimer'sdisease/ patienthandouts. Accessed May 23, 2004.
5. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
6. Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and Alzheimer's disease: A modifiable risk? Free Radic Biol Med 2004;36:1471-1475.
7. Feinstein RE. Cognitive and mental disorders due to general medical conditions. In: Cutler JL, Marcus ER, eds. Saunders text and review series: Psychiatry. Philadelphia: W.B. Saunders Co.;1999:81-104.
8. Bird TD. Alzheimer's disease and other primary dementias. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper D, Hauser SL, Longo DL, eds. Harrison's principles of internal medicine, ed. 14. New York: McGraw-Hill;1998:2348-2355.
9. Kowalska A, Pruchnik-Wolinska D, Florczak J, Modestowicz R, Szczech J, Kozubski W, Rossa G, Wender M. Genetic study of familial cases of Alzheimer's disease. Acta Biochim Pol 2004;51:245-252.
10. Kowalska A, Pruchnik-Wolinska D, Florczak J, Szczech J, Kozubski W, Rossa G, Wender M. Amyloid precursor protein gene analysis in familial Alzheimer's disease cases: A lack of mutations in exons 16 and 17. Folia Neuropathol 2004;42:1-7.
11. Bertram L, Tanzi RE. Alzheimer's disease: One disorder, too many genes? Hum Mol Genet 2004;13 Spec No 1:R135-141.
12. Bertoli-Avella AM, Oostra BA, Heutink P. Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet 2004;114:413-438.
13. Popescu BO, Ankarcrona M. Mechanisms of cell death in Alzheimer's disease: Role of presenilins. J Alzheimers Dis 2004;6:123-128.
14. Marjaux E, Hartmann D, De Strooper B. Presenilins in memory, Alzheimer's disease, and therapy. Neuron 2004;42:189-192.
15. Cummings JL, Mendez MF. Alzheimer's disease and other disorders of cognition. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine, ed. 22. Philadelphia: W.B. Saunders Co.;2004:2253-2255.
16. Grossman RL. Radiologic imaging procedures. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine, ed. 22. Philadelphia: W.B. Saunders Co.;2004:2205-2210.
17. Holm A, Savolainen S, Alafuzoff I. Brain biopsy prior to treatment of Alzheimer's disease. Minim Invasive Neurosurg 2003;46:161-164.
18. Bazin N, Fremont P. [Alzheimer type dementia: Is early diagnosis significant?]. Presse Med 2000;29:871-875.
19. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004;23:94-98.
20. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 2004;38:91-98.
21. Vina J, Lloret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: Prevention of oxidative stress. Mol Aspects Med 2004;25:117-123.
22. Brinton RD. Impact of estrogen therapy on Alzheimer's disease: A fork in the road? CNS Drugs 2004;18:405-422.
23. Gilgun-Sherki Y, Melamed E, Offen D. Antioxidant treatment in Alzheimer's disease: Current state. J Mol Neurosci 2003;21:1-12.
24. Almkvist O, Darreh-Shori T, Stefanova E, Spiegel R, Nordberg A. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol 2004;11:253-261.
25. Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, Shalaby IA, Ramirez A, Nason D, White WF. Pharmacology of selective acetylcholinesterase inhibitors: Implications for use in Alzheimer's disease. Eur J Pharmacol 2004;486:9-17.
26. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-249.
27. Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: Comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry 2003;18:292-297.
28. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer's disease: Current status and new perspectives. Lancet Neurol 2003;2(9):539-47.
29. Jonsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 2003;21:1025-1037.
30. DeLaGarza VW. Pharmacologic treatment of Alzheimer's disease: An update. Am Fam Physician 2003;68:1365-1372.
31. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003;10:633-640.
32. Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: Switching cholinesterase inhibitors. Curr Med Res Opin 2003;19:707-714.
33. Francis PT, Nordberg A, Arnold SE. A pre-clinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005;26:104-111.
34. Schoneich C. Methionine oxidation by reactive oxygen species: Reaction mechanisms and relevance to Alzheimer's disease. Biochim Biophys Acta 2005;1703:111-119.
35. Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA. Gamma- glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. J Neurosci Res 2005;79:700-706.
36. Stoppe G, Pirk O, Haupt M. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine - Utopia?]. Gesundheitswesen 2005;67:20-26.
37. Farlow MR, Lilly ML; ENA713 B352 Study Group. Rivastigmine: An open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005;5:3.
38. Bridgman AM, Wilson MA. The treatment of adult patients with mental disability. Part 1: Consent and duty. Br Dent J 2000;189:66-68.
39. Ocasio NA, Solomowitz BH, Sher MR. Dental management of the patient with Alzheimer's disease. N Y State Dent J 2000;66:32-35.
40. Lapeer GL. Dementia's impact on pain sensation: A serious clinical dilemma for dental geriatric care givers. J Can Dent Assoc 1998;64:182-192.
41. Kocaelli H, Yaltirik M, Yargic LI, Ozbas H. Alzheimer's disease and dental management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:521-524.
42. Mitchell RJ. Etiology of temporomandibular disorders. Curr Opin Dent 1991;1:471-475.
43. Magarian GJ, Middaugh DA, Linz DH. Hyperventilation syndrome: A diagnosis begging for recognition. West J Med 1983;138:733-736.
44. Moody GH, Drummond JR, Newton JP. Alzheimer's disease. Br Dent J 1990;169:45-47.
45. Henry RG. Alzheimer's disease and cognitively impaired elderly: Providing dental care. J Calif Dent Assoc 1999;27:709-717.
46. Kieser J, Jones G, Borlase G, MacFadyen E. Dental treatment of patients with neurodegenerative disease. N Z Dent J 1999;95:130-134.
47. Niessen L, Jones JA. Professional dental care for patients with dementia. Gerodontology 1987;6:67-71.
48. Chalmers JM. Behavior management and communication strategies for dental professionals when caring for patients with dementia. Spec Care Dentist 2000;20:147-154.
49. Nordenram G, Norberg A. Ethical issues in dental management of patients with severe dementia: Ethical reasoning by hospital dentists: A narrative study. Swed Dent J 1998;22:61-76.
50. Brightman VJ. Oral symptoms without apparent physcial abnormality. In: Lynch MA, ed. Burket's oral medicine, diagnosis and treatment, ed. 7. Philadelphia: J.B. Lippincott;1977:576-616.
51. Michels R, Schoenberg BB. Psychogenic disturbances. In: Zegarelli EV, ed. Diagnosis of diseases of the mouth and jaws, ed. 2. Philadelphia: Lea & Febiger;1978.
52. Stiefel DJ, Truelove EL, Menard TW, Anderson VK, Doyle PE, Mandel LS. A comparison of the oral health of persons with and without chronic mental illness in community settings. Spec Care Dent 1990;10:6-12.
53. Friedlander AH, Jarvik LF. The dental management of the patient with dementia. Oral Surg Oral Med Oral Pathol 1987;64:549-553.
54. Steinberg BJ, Brown S. Dental treatment of the health compromised elderly: Medical and psychological considerations. Alpha Omegan 1986;79:34-41.
55. Katz MS, Gerety MB. Gerontology and geriatric medicine. In: Stein JH, ed. Internal medicine, ed. 2.0 [CD-Rom]. St. Louis: Mosby;1998:Chapter 373.
56. Kehoe PG, Katzov H, Andreasen N, Gatz M, Wilcock GK, Cairns NJ, Palmgren J, de Faire U, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. Hum Genet 2004;114:478-483.
57. Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Herholz K, Pupi A. Age and ApoE genotype interaction in Alzheimer's disease: An FDG-PET study. Psychiatry Res 2004;130:141-151.
58. Gard PR. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004;8:7-14.
59. Eikelenboom P, van Gool WA. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 2004;111:281-294.
60. Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003;16:25-30.
61. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003;20:101-113.
62. Rhodus NL. Therapeutic management of common oral lesions. In: Little JW, Falace DA, Miller CS, Rhodus NL, eds. Dental management of the medically compromised patient, ed. 6. St. Louis: Mosby;2002:548-563.